The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
650
Superficial cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
Parabasal cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
Vaginal pH at screening, and weeks 4 and 12.
Most bothersome moderate or severe vulvar/vaginal atrophy sympton at screening, and weeks 4 and 12.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Montgomery, Alabama, United States
Unnamed facility
Scottsdale, Arizona, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Oakland, California, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
Upland, California, United States
Unnamed facility
Denver, Colorado, United States
Unnamed facility
Avon, Connecticut, United States
Unnamed facility
Groton, Connecticut, United States
...and 53 more locations